Mattessich C. Antony's Insider Trades & SAST Disclosures
Mattessich C. Antony's most recent trade in Aura Biosciences Inc was a trade of 14,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 20, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mattessich C. Antony.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aura Biosciences Inc | Antony C. Mattessich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 14,500 | 14,500 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Antony C. Mattessich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 10,500 | 10,500 | - | 0 | Common Stock | |
| Ocular Therapeutix Inc | Antony Mattessich C. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2024 | 549,400 | 549,400 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Mattessich C. Antony | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2024 | 180,400 | 608,343 (1%) | 0% | 0 | Common Stock | |
| Ocular Therapeutix Inc | C. Antony Mattessich | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.86 per share. | 03 Feb 2024 | 19,642 | 588,701 (1%) | 0% | 4.9 | 95,460 | Common Stock |
| Ocular Therapeutix Inc | Mattessich Antony C. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.95 per share. | 31 Jan 2024 | 18,338 | 427,943 (0%) | 0% | 4.9 | 90,773 | Common Stock |
| Ocular Therapeutix Inc | Antony C. Mattessich | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.24 per share. | 06 Feb 2023 | 19,669 | 446,281 (0%) | 0% | 4.2 | 83,397 | Common Stock |
| Ocular Therapeutix Inc | Antony C. Mattessich | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 536,900 | 536,900 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Antony C. Mattessich | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 176,300 | 465,950 (0%) | 0% | 0 | Common Stock | |
| Aura Biosciences Inc | Antony C. Mattessich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Antony C. Mattessich | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2022 | 560,200 | 560,200 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Antony C. Mattessich | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2022 | 186,750 | 289,650 (0%) | 0% | 0 | Common Stock | |
| Ocular Therapeutix Inc | Antony C. Mattessich | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 9.89 per share. | 20 Aug 2021 | 5,000 | 102,900 (0%) | 0% | 9.9 | 49,450 | Common Stock |
| Ocular Therapeutix Inc | Antony C. Mattessich | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 455,000 | 455,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges